BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2026
USD ($)
|
Sep. 30, 2025
USD ($)
|
Sep. 30, 2026
USD ($)
clinicalTrial
|
Sep. 30, 2025
USD ($)
|
|
| Accounting Policies [Abstract] | ||||
| Royalty expense | $ | $ 7,968 | $ 15,407 | $ 39,846 | $ 41,467 |
| Number of phase 3 clinical trials in process | clinicalTrial | 3 | |||